BRIEF—INSYS replaces chief executive

INSYS Therapeutics has appointed Andrew Long as chief executive, replacing Saeed Motahari, who the firm says has “mutually agreed” with the board to step down immediately.

Before serving as chief financial office at Insys, Mr Long was an executive at Abbott Laboratories and Thermo Fisher Scientific.

The firm is dealing with the fallout from a criminal trial of a number of former leaders at the company, related to its marketing of a fentanyl spray.

At the same time, Andrece Housley has been promoted to chief financial officer and Venkat Goskonda has been promoted to chief scientific officer.